🧪
hypothesis

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb as proximal driver in Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration

Hypothesis

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb as proximal driver in Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable proximal phenotype before late disease pathology.
🧬 SNCA🩺 neurodegeneration🎯 Composite 63%💱 $0.57▼9.5%proposed
EvidencePending (0%)📖 6 cit🗣 1 debates 6 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.70 (15%) Evidence 0.62 (15%) Novelty 0.72 (12%) Feasibility 0.67 (12%) Impact 0.64 (12%) Druggability 0.54 (10%) Safety 0.52 (8%) Competition 0.58 (6%) Data Avail. 0.66 (5%) Reproducible 0.61 (5%) KG Connect 0.35 (8%) 0.626 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite63%

🧪 Overview

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable proximal phenotype before late disease pathology. The decisive test is multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["PD Proteogenomic Hub Identification<br/>Multi-Omics Network Analysis"]
    B["Causal Enough: Disease-Associated<br/>Genetics and Transcriptomics Convergence"]
    C["Accessible Enough to Perturb<br/>Drug-Targetable Nodes (kinases, phosphatases)"]
    D["Stage-Specific Hub Activation<br/>Early vs Late PD Neurodegeneration"]
    E["Perturbation-First Validation<br/>CRISPRi, small molecules, siRNA"]
    F["Druggable Target Candidates<br/>Therapeutic Intervention Points"]
    G["Disease-Modifying PD Therapy<br/>Hub-Targeted Neuroprotection"]
    A --> B
    A --> C
    B --> D
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
    style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix6 supports1 contradicts
Supports
Review identified convergent pathogenic mechanisms but highlighted that druggability assessment of network hubs in early PD remains an open challenge.
Key genes and convergent pathogenic mechanisms in
Supports
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
Int J Mol Sci2020PMID:33182554medium
Supports
Neurotrophins and neurodegeneration.
Neuropathol Appl Neurobiol2003PMID:12787319medium
Supports
LRRK2 and neurodegeneration.
Acta Neuropathol2009PMID:19142648medium
Supports
Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson's disease via the prosaposin-GPR37-IL-6 axis.
Cell Rep2025PMID:39913287medium
Supports
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.
Neurology2012PMID:22722629medium
Contradicts
network hubs are often essential, pleiotropic, or inaccessible to safe pharmacologic modulation
Key genes and convergent pathogenic mechanisms in
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SNCA

🧬 PDB 1XQ8 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SNCA →

No DepMap CRISPR Chronos data found for SNCA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.5%
Volatility
Low
0.0019
Events (7d)
2
Price History
▼9.5%

💾 Resource Usage

LLM Tokens
172,526
$0.6062
API Calls
85
Total Cost
$0.6062

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF we stratify early-stage PD patients (disease duration <3 years, H&Y stage ≤2) by druggable proteogenomic hub accessibility scores (CNS penetrance ≥30%, DrugBank hit) and compare to age-matched contHigh-hub-accessibility PD patients will show ≥2-fold increase in CSF synaptic dysfunction biomarkers compared to low-accessibility PD patients and ≥3-fold incre— no observation —pending0.68
IF we CRISPR-perturb top-ranked proteogenomic hub genes (identified by multi-omics network centrality >2 SD above mean) in SNCA-A53T iPSC-derived dopaminergic neurons, THEN we will observe a significaHub-perturbed neurons will show ≥40% reduction in synaptic vesicle markers and ≥50% decrease in spontaneous firing rate relative to control perturbations.— no observation —pending0.72
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF we CRISPR-perturb top-ranked proteogenomic hub genes (identified by multi-omics network centrality >2 SD above mean) in SNCA-A53T iPSC-derived dopaminergic neurons, THEN we will observe a significant decrease in synaptic vesicle release probability (measured by vGlut1/parkin colocalization and sp
Predicted outcome: Hub-perturbed neurons will show ≥40% reduction in synaptic vesicle markers and ≥50% decrease in spontaneous firing rate relative to control perturbati
Falsification: Non-hub gene perturbations produce equivalent or greater synaptic dysfunction than hub perturbations, indicating network centrality does not predict proximal phenotype.
pendingconf 68%
IF we stratify early-stage PD patients (disease duration <3 years, H&Y stage ≤2) by druggable proteogenomic hub accessibility scores (CNS penetrance ≥30%, DrugBank hit) and compare to age-matched controls, THEN cerebrospinal fluid levels of synaptic dysfunction markers (beta-synuclein ratio, CSPG fr
Predicted outcome: High-hub-accessibility PD patients will show ≥2-fold increase in CSF synaptic dysfunction biomarkers compared to low-accessibility PD patients and ≥3-
Falsification: CSF synaptic biomarkers show no significant difference between high and low hub-accessibility PD strata, indicating hub accessibility does not predict proximal synaptic pathology.
View on SciDEX ↗